

Stefano Piaserico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2917788/publications.pdf>

Version: 2024-02-01

162
papers

4,852
citations

101496

36
h-index

118793

62
g-index

162
all docs

162
docs citations

162
times ranked

4879
citing authors

#	ARTICLE	IF	CITATIONS
1	Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 367-376.	1.4	9
2	Multiparametric analysis of coronary flow in psoriasis using a coronary flow reserve companion. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13711.	1.7	6
3	Whole-Exome Sequencing in 10 Unrelated Patients with Syndromic Hidradenitis Suppurativa: A Preliminary Step for a Genotype-Phenotype Correlation. <i>Dermatology</i> , 2022, 238, 860-869.	0.9	28
4	Efficacy and safety of guselkumab in two psoriatic patients with hepatitis B and C virus infection. <i>Dermatologic Therapy</i> , 2022, 35, e15281.	0.8	2
5	Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 547-554.	1.4	8
6	Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study. <i>Dermatology</i> , 2022, 238, 897-903.	0.9	5
7	Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, 1-78.	0.1	25
8	The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2443-2454.	1.1	8
9	Pharmacological management of severe plaque psoriasis in patients with cardiovascular disease. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , 1-12.	0.9	1
10	Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. <i>Journal of Clinical Medicine</i> , 2022, 11, 2801.	1.0	6
11	Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	10
12	Clinicopathological features, <scp>MCPyV</scp> status and outcomes of Merkel cell carcinoma in <scp>solidâ€œorgan</scp> transplant recipients: a retrospective, multicentre cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1991-2001.	1.3	8
13	Xeroderma Pigmentosum: A Genetic Condition Skin Cancer Correlatedâ€œA Systematic Review. <i>BioMed Research International</i> , 2022, 2022, 1-12.	0.9	7
14	Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. <i>Clinical Rheumatology</i> , 2021, 40, 2251-2262.	1.0	10
15	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€œinsights from a global registryâ€œbased study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	1.5	136
16	Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 271-277.	1.4	40
17	Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 558-560.e1.	1.5	44
18	Correspondence on â€œRecovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumabâ€œ™. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e79-e79.	0.5	9

#	ARTICLE	IF	CITATIONS
19	Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00576.	0.6	5
20	Skin cancers in Italian lung transplant recipients: Incidence and risk factors analysis. <i>Dermatologic Therapy</i> , 2021, 34, e14749.	0.8	0
21	Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis. <i>European Journal of Dermatology</i> , 2021, 31, 3-16.	0.3	10
22	Insights into Sarsâ€CoVâ€2 vaccination in patients with chronic plaque psoriasis on systemic treatments. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e361-e362.	1.3	9
23	Is SARSâ€CoVâ€2 screening test indicated for psoriasis patients candidate to biologic therapy?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e355-e357.	1.3	2
24	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	3.3	65
25	Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review. <i>Dermatology and Therapy</i> , 2021, 11, 695-705.	1.4	17
26	Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis. <i>BioDrugs</i> , 2021, 35, 469-471.	2.2	7
27	Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. <i>British Journal of Dermatology</i> , 2021, 185, 323-334.	1.4	55
28	Sequential treatment with calcitriol and methyl aminolevulinate-daylight photodynamic therapy for patients with multiple actinic keratoses of the upper extremities. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 34, 102325.	1.3	8
29	Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs. <i>Dermatology and Therapy</i> , 2021, 11, 1333-1343.	1.4	17
30	Impact of the COVID-19 pandemic on melanoma diagnosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e714-e715.	1.3	20
31	Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. <i>Journal of Investigative Dermatology</i> , 2021, , .	0.3	9
32	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. <i>Dermatology and Therapy</i> , 2021, 11, 235-252.	1.4	34
33	Diagnosis and management of cutaneous and anogenital lichen sclerosus: recommendations from the Italian Society of Dermatology (SIDeMaST). <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 519-533.	0.1	3
34	Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. <i>Psoriasis: Targets and Therapy</i> , 2021, Volume 11, 151-168.	1.2	10
35	The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1099-1107.	0.4	2
36	Perianal ulcer caused by <i>Serratia marcescens</i> . <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 256-257.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 476-483.	1.1	23
38	Zoon Balanitis: misdiagnosis or missed diagnosis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e117-e118.	1.3	0
39	European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: emerging indications " field cancerization, photorejuvenation and inflammatory/infective dermatoses. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 17-29.	1.3	78
40	Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e770-e772.	1.3	31
41	Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 749-751.	3.3	27
42	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2839-2845.	1.3	6
43	Switching from one infliximab biosimilar (CTP13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2020, 183, 397-398.	1.4	17
44	Consensus on the place in therapy of TNF- α inhibitors in the treatment of patients with chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e470-e472.	1.3	6
45	Efficacy of topical photodynamic therapy in the treatment of erythroplasia of Queyrat. <i>Dermatology Reports</i> , 2020, 12, 8566.	0.4	2
46	REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19. <i>Journal of Infection</i> , 2020, 81, e37-e38.	1.7	2
47	Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2499-2504.	1.3	96
48	Italian expert consensus paper on the management of patients with actinic keratoses. <i>Dermatologic Therapy</i> , 2020, 33, e13992.	0.8	12
49	The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. <i>British Journal of Dermatology</i> , 2020, 183, 373-374.	1.4	104
50	SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e254-e255.	1.3	54
51	Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1196-1201.	1.3	85
52	TNF- α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 591-598.	1.3	18
53	Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives. <i>Current Vascular Pharmacology</i> , 2020, 18, 592-609.	0.8	6
54	Psoriasis and Dementia: A Cross-sectional Study of 121,801 Patients. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00250.	0.6	10

#	ARTICLE	IF	CITATIONS
55	SAT0412â€¦ACCURACY OF AN INSTRUMENT FOR SCREENING PSORIATIC ARTHRITIS AMONG PSORIATIC PATIENTS: RESULTS FROM THE MULTICENTRE ITALIAN STUDY HERACLES (SCREENING STRATEGIES FOR) Tj ETQq1 1 0.784314rgBT /Overlock 10 T of the Rheumatic Diseases, 2020, 79, 1158.2-1159.	0.5	0
56	A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study). Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 392-399.	0.8	4
57	Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clinical Rheumatology, 2019, 38, 2843-2850.	1.0	39
58	P377Arrhythmogenic cardiomyopathy in epidermolysis bullosa: are desmosomes at fault for both?. European Heart Journal Cardiovascular Imaging, 2019, 20, .	0.5	0
59	Long-term prognostic value of coronary flow reserve in psoriasis patients. Atherosclerosis, 2019, 289, 57-63.	0.4	23
60	Osteoporotic vertebral fracture caused by topical corticosteroid abuse: A case report. Experimental and Therapeutic Medicine, 2019, 18, 2746-2748.	0.8	1
61	Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. American Journal of Clinical Dermatology, 2019, 20, 829-845.	3.3	28
62	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. Journal of the American Academy of Dermatology, 2019, 81, 273-275.	0.6	39
63	Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. British Journal of Dermatology, 2019, 182, 175-179.	1.4	3
64	Secukinumab shows high efficacy irrespective of <i>HLAâ€ƒCw6</i> status in patients with moderateâ€ƒtoâ€ƒsevere plaqueâ€ƒtype psoriasis: results from extension phase of the SUPREME study. British Journal of Dermatology, 2019, 181, 413-414.	1.4	21
65	A caseâ€ƒcontrol study of risk factors associated with Zoon balanitis in men. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1591-1594.	1.3	7
66	Pruritus characteristics in a large Italian cohort of psoriatic patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1316-1324.	1.3	46
67	European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications â€ƒ actinic keratoses, Bowen's disease and basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2225-2238.	1.3	118
68	Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. British Journal of Dermatology, 2019, 180, 1547-1548.	1.4	30
69	Accuracy of dermoscopy in distinguishing erythroplasia of Queyrat from common forms of chronic balanitis: results from a multicentric observational study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 966-972.	1.3	23
70	Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 376-377.	0.8	3
71	Italian Guidelines in diagnosis and treatment of alopecia areata. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 609-623.	0.8	39
72	Eczematous, Pruritic, Brownish Plaque of the Nipple and Areola: A Quiz. Acta Dermato-Venereologica, 2019, 99, 1317-1318.	0.6	2

#	ARTICLE	IF	CITATIONS
73	A Case of Secondary Osteoma Cutis Associated with Lichen Planopilaris. <i>Acta Dermato-Venereologica</i> , 2019, 99, 1190-1191.	0.6	1
74	Herpes simplex reactivation after photodynamic therapy for actinic cheilitis in a patient with non-Hodgkin lymphoma: a possible indication for prophylaxis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 736-737.	0.8	0
75	Comorbidities in Autoimmune Skin Diseases. <i>JAMA Dermatology</i> , 2018, 154, 264.	2.0	0
76	Simulating the life course of psoriasis patients: the interplay between therapy intervention and marital status. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 62-67.	1.3	4
77	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 515-528.	1.3	15
78	Central Obesity in Children with Psoriasis. <i>Acta Dermato-Venereologica</i> , 2018, 98, 282-283.	0.6	20
79	How to improve adherence to treatment in patients with mild-to-moderate psoriasis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 692-697.	0.8	7
80	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1853-1859.	1.3	27
81	Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 774-790.	1.3	140
82	Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 253-271.	3.3	49
83	The heart of the problem. <i>British Journal of Dermatology</i> , 2017, 176, 849-850.	1.4	0
84	Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2017, 177, e325-e326.	1.4	19
85	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. Reply to Dr. Ricceri letter. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e486-e487.	1.3	2
86	Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. <i>Dermatologic Therapy</i> , 2017, 30, e12503.	0.8	10
87	Painful skin lesions and squamous cell carcinoma predict overall mortality risk in organ transplant recipients: a cohort study. <i>British Journal of Dermatology</i> , 2017, 176, 1179-1186.	1.4	5
88	Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. <i>European Journal of Dermatology</i> , 2017, 27, 599-608.	0.3	30
89	Brownish-grey, Papular Scaling Rash on the Trunk and Lower Limbs: A Quiz. <i>Acta Dermato-Venereologica</i> , 2017, 97, 769-771.	0.6	1
90	Atrophic pityriasis versicolor occurring in a patient with Sjögren's syndrome. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016218108.	0.2	5

#	ARTICLE	IF	CITATIONS
91	Symmetrical, Hypopigmented Papules and Plaques on the Palms Induced by Contact with Water: A Quiz. <i>Acta Dermato-Venereologica</i> , 2016, 96, 575-576.	0.6	2
92	Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. <i>Acta Dermato-Venereologica</i> , 2016, 96, 251-252.	0.6	21
93	Italian expert consensus for the management of actinic keratosis in immunocompetent patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1077-1084.	1.3	41
94	Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. <i>Atherosclerosis</i> , 2016, 251, 25-30.	0.4	47
95	Assessing the Impact of Atopic Dermatitis on the Patients' Parents with the Visual Instrument "Caregiver-PRISM". <i>Dermatology</i> , 2016, 232, 490-495.	0.9	7
96	TLR7 Gln11Leu single nucleotide polymorphism and response to treatment with imiquimod in patients with basal cell carcinoma: a pilot study. <i>Pharmacogenomics</i> , 2015, 16, 1913-1917.	0.6	10
97	Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1718-1723.	1.3	92
98	Daylight photodynamic therapy with methyl-aminolevulinate for the treatment of actinic cheilitis. <i>Dermatologic Therapy</i> , 2015, 28, 355-368.	0.8	21
99	Polypodium Leucotomos Supplementation in the Treatment of Scalp Actinic Keratosis. <i>Dermatologic Surgery</i> , 2015, 41, 898-902.	0.4	22
100	Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis. <i>Journal of Dermatological Science</i> , 2015, 78, 149-151.	1.0	21
101	European Dermatology Forum Guidelines on topical photodynamic therapy. <i>European Journal of Dermatology</i> , 2015, 25, 296-311.	0.3	125
102	Autochthonous Hookworm-Related Cutaneous Larva Migrans Disease in Northeastern Italy: A Case Report. <i>Journal of Parasitology</i> , 2015, 101, 488-489.	0.3	7
103	<scp>PSOCUBE</scp>, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1310-1317.	1.3	8
104	Efficacy of Biofeedback and Cognitive-behavioural Therapy in Psoriatic Patients: A Single-blind, Randomized and Controlled Study with Added Narrow-band Ultraviolet B Therapy. <i>Acta Dermato-Venereologica</i> , 2014, 96, 91-5.	0.6	15
105	Validation and Field Performance of the Italian Version of the Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire. <i>Acta Dermato-Venereologica</i> , 2014, 96, 96-101.	0.6	4
106	Psoriasis "The Life Course Approach". <i>Acta Dermato-Venereologica</i> , 2014, 96, 102-8.	0.6	4
107	Quality of Life Assessment of Patients with Scalp Dermatitis Using the Italian Version of the Scalpdex. <i>Acta Dermato-Venereologica</i> , 2014, 94, 411-414.	0.6	25
108	Rejection-mediated Regression of Melanocytic Naevi in an Immunosuppressed Organ Transplant Recipient. <i>Acta Dermato-Venereologica</i> , 2014, 94, 733-734.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Efficacy and Safety of Systemic Treatments for Psoriasis in Elderly Patients. <i>Acta Dermato-Venereologica</i> , 2014, 94, 293-297.	0.6	71
110	Pain Identifies Squamous Cell Carcinoma in Organ Transplant Recipients: The SCOPE-ITSCC PAIN Study. <i>American Journal of Transplantation</i> , 2014, 14, 668-676.	2.6	16
111	Effects of TNF-Alpha Inhibitors on Circulating Th17 Cells in Patients Affected by Severe Psoriasis. <i>Drug Development Research</i> , 2014, 75, S73-S76.	1.4	14
112	Consensus recommendations for the treatment of basal cell carcinomas in <sc>G</sc> orlin syndrome with topical methylaminolaevulinateâ€photodynamic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 626-632.	1.3	44
113	Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 257-262.e3.	0.6	54
114	Management of Patients with Psoriasis Treated with Biological Drugs Needing a Surgical Treatment. <i>Drug Development Research</i> , 2014, 75, S24-S26.	1.4	19
115	Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis. <i>European Journal of Dermatology</i> , 2014, 24, 133-135.	0.3	12
116	Kaposi's sarcoma and other rare skin cancers in organ transplant patients. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2014, 149, 395-400.	0.8	1
117	Cutaneous viral infections in organ transplant patients. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2014, 149, 409-15.	0.8	15
118	Photodynamic therapy for actinic keratosis in organ transplant patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 57-66.	1.3	50
119	Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2013, 24, 305-311.	1.1	28
120	Effects of TNF-alpha inhibitors on the number of epidermal Langerhans cells in uninvolved skin of psoriatic patients: A pilot study. <i>Acta Histochemica</i> , 2013, 115, 767-769.	0.9	1
121	Immunogenicity of anti-TNFÎ± therapy in psoriasis: a clinical issue?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1673-1682.	1.4	56
122	Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. <i>British Journal of Dermatology</i> , 2013, 168, 1124-1127.	1.4	67
123	Cumulative Life Course Impairment in Melanoma and Nonmelanoma Skin Cancer. <i>Current Problems in Dermatology</i> , 2013, 44, 118-124.	0.8	3
124	Skin Cancer and Other Cutaneous Disorders in Liver Transplant Recipients. <i>Acta Dermato-Venereologica</i> , 2012, 92, 411-415.	0.6	34
125	Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies. <i>Immunopharmacology and Immunotoxicology</i> , 2012, 34, 901-906.	1.1	3
126	Impaired coronary flow reserve in young patients affected by severe psoriasis. <i>Atherosclerosis</i> , 2012, 221, 113-117.	0.4	65

#	ARTICLE	IF	CITATIONS
127	Psoriasis segmentation through chromatic regions and Geometric Active Contours. , 2012, 2012, 5388-91.		9
128	Psodisk, a new visual method for assessing the burden of psoriasis on patients. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1163-1166.	1.3	26
129	Bullous Scabies Simulating Pemphigoid. Journal of Cutaneous Medicine and Surgery, 2011, 15, 55-57.	0.6	10
130	Incidence and clinical predictors of primary opportunistic deep cutaneous mycoses in solid organ transplant recipients: a multicenter cohort study. Clinical Transplantation, 2010, 24, 328-333.	0.8	12
131	<i>PTCH1</i> gene haplotype association with basal cell carcinoma after transplantation. British Journal of Dermatology, 2010, 163, 364-370.	1.4	18
132	Melanoma and Immunosuppression. Dermatology, 2009, 218, 88-88.	0.9	11
133	Generalized Granuloma Annulare Treated with Methylaminolevulinate Photodynamic Therapy. Dermatology, 2009, 218, 282-284.	0.9	21
134	Acne Keloidalis of the Scalp in a Renal Transplant Patient Treated with Cyclosporine. Acta Dermato-Venereologica, 2009, 89, 312-313.	0.6	8
135	Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma in a Heart Transplant Patient: Case Report and Literature Review. Acta Dermato-Venereologica, 2009, 89, 74-77.	0.6	19
136	Kobner phenomenon in psoriasis induced by Mantoux test. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1103-1105.	1.3	7
137	Immunosuppression and melanocyte proliferation. Melanoma Research, 2009, 19, 63-68.	0.6	61
138	Squamous Cell Carcinoma. Cancer Treatment and Research, 2009, 146, 241-261.	0.2	7
139	Melanoma in Organ Transplant Recipients: Clinicopathological Features and Outcome in 100 Cases. American Journal of Transplantation, 2008, 8, 1891-1900.	2.6	107
140	Topical Photodynamic Therapy of Actinic Keratosis in Renal Transplant Recipients. Transplantation Proceedings, 2007, 39, 1847-1850.	0.3	75
141	Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. British Journal of Dermatology, 2007, 157, 49-57.	1.4	35
142	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. British Journal of Dermatology, 2007, 157, 68-73.	1.4	543
143	Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. Journal of the American Academy of Dermatology, 2006, 54, 338-340.	0.6	30
144	Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. Experimental Dermatology, 2006, 15, 958-965.	1.4	29

#	ARTICLE	IF	CITATIONS
145	Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. <i>European Journal of Dermatology</i> , 2006, 16, 553-7.	0.3	30
146	Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn's disease. <i>Melanoma Research</i> , 2005, 15, 223-224.	0.6	18
147	C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. <i>Transplant International</i> , 2005, 18, 116-124.	0.8	27
148	Abnormal total ejection isovolume index as early noninvasive marker of chronic rejection in heart transplantation*. <i>Transplant International</i> , 2005, 18, 303-308.	0.8	7
149	Skin disorders in patients transplanted in childhood. <i>Transplant International</i> , 2005, 18, 360-365.	0.8	17
150	Immunosuppressive Level and Other Risk Factors for Basal Cell Carcinoma and Squamous Cell Carcinoma in Heart Transplant Recipients. <i>Archives of Dermatology</i> , 2004, 140, 1079-85.	1.7	105
151	Posttraumatic Port-Wine Stain in a 4-Year-Old Girl: Fegeler Syndrome. <i>Pediatric Dermatology</i> , 2004, 21, 131-133.	0.5	18
152	Immune and Nonimmune Predictors of Cardiac Allograft Vasculopathy Onset and Severity: Multivariate Risk Factor Analysis and Role of Immunosuppression. <i>American Journal of Transplantation</i> , 2004, 4, 962-970.	2.6	129
153	Allergic contact sensitivity in elderly patients. <i>Aging Clinical and Experimental Research</i> , 2004, 16, 221-225.	1.4	37
154	Eruptive melanocytic nevi in patients with renal allografts: Report of 10 cases with dermoscopic findings. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 1020-1022.	0.6	65
155	Monoclonal gammopathy in heart transplantation: risk factor analysis and relevance of immunosuppressive load. <i>Transplantation Proceedings</i> , 2001, 33, 1583-1584.	0.3	14
156	High rejection score in the first year and risk of skin cancer in heart transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1608-1609.	0.3	2
157	De novo noncutaneous malignancies in heart transplantation: a single-centre 15-year experience and risk factor analysis. <i>Transplantation Proceedings</i> , 2001, 33, 3658-3659.	0.3	6
158	PIBI(D)S: clinical and molecular characterization of a new case. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 65-69.	1.3	9
159	Diaminodiphenylmethane (DDM): frequency of sensitization, clinical relevance and concomitant positive reactions. <i>Contact Dermatitis</i> , 2001, 44, 283-288.	0.8	18
160	Skin Cancer in Heart Transplant Recipients : Risk Factor Analysis and Relevance of Immunosuppressive Therapy. <i>Circulation</i> , 2000, 102, III-222-III-227.	1.6	99
161	RISK OF NONMELANOMA SKIN CANCER IN ITALIAN ORGAN TRANSPLANT RECIPIENTS. A REGISTRY-BASED STUDY. <i>Transplantation</i> , 2000, 70, 1479-1484.	0.5	104
162	Skin cancer in heart transplant recipients: frequency and risk factor analysis. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 249-255.	0.3	121